News
GNMSF
284.84
NaN%
--
Weekly Report: what happened at GNMSF last week (0415-0419)?
Weekly Report · 5d ago
Transactions in Connection with Share Buy-back Program Genmab
Barchart · 6d ago
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Net trade sales of DARZALEX were USD 2,692 million in the first quarter of 2024 in the U.S. And the rest of the world. Genmab receives royalties on the worldwide net sales of daratumumab under the exclusive worldwide license to janssen.
Barchart · 04/16 05:24
Weekly Report: what happened at GNMSF last week (0408-0412)?
Weekly Report · 04/15 11:56
Transactions in Connection with Share Buy-back Program Genmab
Barchart · 04/15 03:07
Weekly Report: what happened at GNMSF last week (0401-0405)?
Weekly Report · 04/08 12:02
Transactions in Connection with Share Buy-back Program
Barchart · 04/08 04:44
Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal
Healthcare M&A Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal. Profound bio has developed a pipeline of drug candidates targeting solid tumors and hematological malignancies. The proposed deal is expected to close in the first half of 2024.
Seeking Alpha · 04/03 08:17
Transactions in Connection with Share Buy-back Program
Barchart · 04/02 02:24
Weekly Report: what happened at GNMSF last week (0325-0329)?
Weekly Report · 04/01 11:59
Weekly Report: what happened at GNMSF last week (0318-0322)?
Weekly Report · 03/25 12:02
Transactions in Connection with Share Buy-back Program
Denmark's Genmab A/S announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The program is expected to be completed no later than December 16, 2024. The company will buy back shares.
Barchart · 03/25 08:31
Weekly Report: what happened at GNMSF last week (0311-0315)?
Weekly Report · 03/18 12:00
Completion of share buy-back program
Barchart · 03/18 04:49
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to constitute itself. It was decided to grant 12,847 restricted stock units to members of the Board and employees of the Company.
Barchart · 03/13 15:53
Passing of Genmab A/S’ Annual General Meeting
Genmab A/S held its Annual General Meeting in Copenhagen, Denmark on March 13, 2024. The Company's plans for 2024 were presented. The Annual Report for 2023 was endorsed by the previous auditors, PricewaterhouseCoopers. The Board of Directors approved the report.
Barchart · 03/13 10:13
Weekly Report: what happened at GNMSF last week (0304-0308)?
Weekly Report · 03/11 11:55
Transactions in connection with share buy-back program
Barchart · 03/11 04:42
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (Nasdaq: GMAB) discloses the data of the transactions made in Genmab by managerial employees and their closely associated persons. The company is listed on the Copenhagen Stock Exchange. The transaction data is disclosed in accordance with regulations.
Barchart · 03/04 12:10
Weekly Report: what happened at GNMSF last week (0226-0301)?
Weekly Report · 03/04 11:59
More
Webull provides a variety of real-time GNMSF stock news. You can receive the latest news about Genmab A/S through multiple platforms. This information may help you make smarter investment decisions.
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.